MarginsXMarginsX
Home › Markets › Health Care › RNXT

RenovoRx Inc. (RNXT)

RNXT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9549
-8.18% on the day
Market cap
$46.1M
Nano cap
Revenue · 2025
$1.1M
+2511.6% on 2024
Net income · 2025
-$11.2M
-994.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/0001193125-26-131928-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRNXT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001574094
SEC industry codeSurgical & Medical Instruments & Apparatus
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.1M
Net income-$11.2M
Operating income-$12.5M
Net margin-994.5%
Operating margin-1114.0%
Revenue growth+2511.6%
Cash$7.0M
Total assets$8.1M
P/E (computed)Net income was not positive
P/S (computed)41.0×

Warning signs

Cash runway
10.3 months
$10.4M cash at September 30, 2026
Share count, 1 year
+31.7%
2025-11-12 to 2026-10-30 · +351.2% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$84K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$10.4M cash; operating cash flow -$3.0M a quarter.Report 2026-09-30
Shares outstanding48,250,592 (2026-10-30); 36,649,916 a year earlier; 10,693,580 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-04-16
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-02
AuditorFrank, Rimerman & Co. LLP, San Francisco, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $84K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.1M-$3.6M-$2.5M$10.4MNo debt tags$2.8M10-Q 2026-11-05
Q2 2026
2026-06-30
$909K-$2.9M-$2.9M$9.5MNo debt tags$2.0M10-Q 2026-08-13
Q1 2026
2026-03-31
$563K-$3.5M-$3.7M$12.4MNo debt tags$1.5M10-Q 2026-05-14
Q4 2025
2025-12-31
$238K-$2.9M-$3.0M$7.0MNo debt tags$1.1M10-K 2026-03-30
Q3 2025
2025-09-30
$266K-$2.9M-$2.3M$10.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
$422K-$2.9M-$2.3M$12.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
$197K-$2.4M-$3.4M$14.6MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$2.9M-$2.4M$7.2MNo debt tags$43K10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-27
Latest annual report10-K/A2026-05-15
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 293 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.0%
1 month-9.6%
3 months-17.5%
Year to date+23.8%
1 year+6.8%
From 52-week high-58.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ANVSAnnovis Bio Inc.$0.7500-19.02%$46.5M
MISTMilestone Pharmaceuticals Inc. Common Shares$0.3650-29.81%$45.4M
ATNMActinium Pharmaceuticals Inc. (Delaware)$1.49-9.15%$46.8M
NMADNomad Power Solutions Inc.$2.80+19.15%$45.1M
TLPHTalphera Inc.$0.8609-4.98%$44.7M
HYFTMindWalk Holdings Corp.$0.9378-8.95%$44.6M
ONCYOncolytics Biotech Inc.$0.3399-8.14%$44.6M
HOWLWerewolf Therapeutics Inc.$0.9908+1.07%$48.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier